Athersys, Inc.

328 articles about Athersys, Inc.

• Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

  11/16/2023

  Athersys, Inc. announced financial results for the three and nine months ended September 30, 2023 and provided a business update.

• Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

  10/16/2023

  Athersys, Inc. announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K.

• Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

  10/10/2023

  Athersys, Inc. announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem ® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365.

• Athersys Licenses its Animal Health Assets to Ardent Animal Health

  10/3/2023

  Athersys, Inc., a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, and Multipotent Adult Progenitor Cell technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health.

• Athersys Director Jane Wasman Appointed Board Chair

  10/2/2023

  Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders.

• Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation

  9/6/2023

  Athersys, Inc. announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation’s Medical Research Council to explore the potential use of Athersys’ MultiStem cellular therapy during machine perfusion prior to kidney transplantation.

• Athersys, Inc. Announces Pricing of $3.5 Million Public Offering

  8/18/2023

  Athersys, Inc., announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock at a purchase price of $0.32 per share.

• Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

  8/16/2023

  Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update.

• Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

  8/11/2023

  Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced the appointment of Neema Mayhugh, PhD to its Board of Directors.

• Athersys to Host Business Update Conference Call on August 9th

  7/31/2023

  Athersys, Inc., a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, announced it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time.

• Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma

  6/1/2023

  Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients following resuscitation from hemorrhagic trauma.

• Athersys Restructures Debt with Supplier

  5/23/2023

  Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier.

• Athersys Reports First Quarter 2023 Financial Results and Business Highlights

  5/18/2023

  Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update.

• Athersys to Participate in Three Upcoming Conferences

  5/8/2023

  Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announced its participation in three upcoming conferences during the month of May.

• Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference

  5/1/2023

  Athersys, Inc. announced today their participation in the Cellular Therapeutics in Trauma and Critical Care’s (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona.

• Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference

  4/21/2023

  Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL.

• Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement

  4/19/2023

  Athersys, Inc. announced that it has closed its previously announced offering to sell 3,685,000 shares of the Company’s common stock in a registered direct offering and warrants to purchase 3,685,000 Shares at a purchase price per Share of $1.00 in a concurrent private placement.

• Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement

  4/18/2023

  Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 3,685,000 Shares at a purchase price per Share.

• Athersys to Host Business Update Conference Call on April 20th

  4/10/2023

  Athersys, Inc., a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, announced it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time.

• Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

  3/31/2023

  Athersys, Inc. announced financial results for the three and 12 months ended December 31, 2022, and provided a business update.